EXHIBIT 16.1
October 19, 2022
U.S. Securities and Exchange Commission
Office of the Chief Accountant
100 F Street NE
Washington, DC 20549
Re: QLY BIOTECH GROUP CORP.
Ladies and Gentlemen:
We have read the statements under item 4.01 in the Form 8-K dated October 19, 2022, of QLY BIOTECH GROUP CORP. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm in the Form 8-K.
Respectfully submitted,
/s/ Michael Gillespie & Associates, PLLC
Seattle, Washington
October 19, 2022
